Zai Lab appoints former Biogen CEO Michel Vounatsos as independent director

Zai Lab Ltd

Appointed Michel Vounatsos independent director effective Jan 7, 2023; chairs Commercial Committee and serves on R&D.
Vounatsos was Biogen CEO (2017-2022) and previously President of MSD China; brings global and China commercial expertise.
Compensation: $50k annual retainer, $15k for Commercial chair, $7.5k for R&D; restricted shares $750k vesting over 3 years.
Press release notes Zai Lab has four marketed medicines and plans three more launches in near term.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michel Vounatsos

independent director

ZLAB · Zai Lab Ltd

Effective: 2023-01-07
Filed: January 9, 2023, 6:59 PM ET

On January 7, 2023, the Board of Directors (the “Board”) of Zai Lab Limited (the “Company”) appointed Michel Vounatsos as an independent director, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michel Vounatsos was appointed as independent director at Zai Lab Ltd.

Action: appointed
Role: independent director

Exact text from the filing

On January 7, 2023, the Board of Directors (the “Board”) of Zai Lab Limited (the “Company”) appointed Michel Vounatsos as an independent director, effective immediately.

View on SEC.gov

Zai Lab Ltd filing history →

Source: SEC EDGAR

accession 0001628280-23-000722

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.